ClearPoint Neuro — Third Quarter 2026 Earnings Summary

ClearPoint Neuro reported third-quarter 2026 revenue of $12.1 million, reflecting a 36% year-over-year increase driven by the integration of the IRRAflow portfolio. Neurosurgery navigation and therapy revenue grew 59% to $5.4 million, while biologics and drug delivery revenue rose 11% to $4.9 million. The company achieved a gross margin of 58% and reported a net loss of $7.46 million for the quarter, with operating expenses increasing 23% to $13.4 million. As of September 30, 2026, ClearPoint Neuro held $46.2 million in cash and cash equivalents following $22.0 million in proceeds from an at-the-market equity offering.